

Haematologica
HAEMATOL/2017/165720
Version 2

Complement C3 is a novel modulator of the anti-FVIII immune response

Julie Rayes, Mathieu Ing, Sandrine Delignat, Ivan Peyron, Laurent Gilardin, Carl-Wilhelm Vogel, David C Fritzinger, Véronique Frémeaux-Bacchi, Srinivas V Kaveri, Lubka T Roumenina, and Sébastien Lacroix-Desmazes

Disclosures: This study was supported by Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Université Pierre et Marie Curie (UPMC) Paris 6, and by a grant from Pfizer (Aspire Haemophilia Research award 2016 WI212828). MI and IP were recipients of fellowships from Ministère de l'enseignement supérieur et de la recherche. LG was the recipient of a "poste d'accueil INSERM" fellowship. FVIIIHSQ in the ReNeo plasmid and BHK-M cells were kind gifts from Prof Pete Lollar (Aflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University, Atlanta, GA, USA). Recombinant ADAMTS-13 and FVIII were kind gifts from Baxter Innovations GmbH (Vienna, Austria), and CSL-Behring (Marburg, Germany), respectively. We also would like to thank the staff from the Centre d'Imagerie Cellulaire et Cytométrie platform and Centre d'Expérimentation Fonctionnelle for assistance (Centre de Recherche des Cordeliers, Paris). JR and MI contributed equally to the work CWV, JR and SLD: patent application pending on the use of hCVF as a method for prevention of immunogenicity related to biologics therapy (PCT/US2015/035693) Other authors have no conflict of interest

Contributions: Designed research: JR, MI, CWV, VFB, LTR, SVK, SLD Performed experiments : JR, MI, IP, SD, LG, CWV, DCF Analyzed data : JR, MI, VFB, LTR, SLD Wrote the paper: JR, MI, CWV, LTR, SLD